A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)

被引：0
|
作者：
Hiroyuki Uetake
Masamichi Yasuno
Megumi Ishiguro
Shingo Kameoka
Yasuhiro Shimada
Keiichi Takahashi
Toshiaki Watanabe
Kei Muro
Hideo Baba
Junji Yamamoto
Nobuyuki Mizunuma
Hiroshi Tamagawa
Izumi Mochizuki
Yusuke Kinugasa
Takashi Kikuchi
Kenichi Sugihara
机构：
[1] Tokyo Medical and Dental University,Department of Translational Oncology, Graduate School
[2] Tokyo Metropolitan Hiroo Hospital,Department of Surgery
[3] Tokyo Women’s Medical University,Department of Surgery II
[4] National Cancer Center Hospital,Division of Gastrointestinal Medical Oncology
[5] Tokyo Metropolitan Cancer and Infectious Disease Center,Colorectal Surgical Division, Department of Surgery
[6] Komagome Hospital,Department of Surgical Oncology, Graduate School of Medicine
[7] The University of Tokyo,Clinical Oncology
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery, Graduate School of Medical Science
[9] Kumamoto University,Department of Surgery
[10] National Defense Medical College,Gastroenterological Center
[11] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Surgery
[12] Osaka General Medical Center,Department of Surgery
[13] Iwate Prefectural Central Hospital,Gastrointestinal Surgery Division
[14] Shizuoka Cancer Center,Department of Statistical Analysis
[15] Translational Research Informatics Center,Department of Surgery Oncology
[16] Tokyo Medical and Dental University,undefined
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Bevacizumab; Liver Metastasis; Sixth Cycle; Resectable Liver Metastasis; High Adverse Event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：908 / 915
页数：7
相关论文
共 50 条
  • [1] A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)
    Uetake, Hiroyuki
    Yasuno, Masamichi
    Ishiguro, Megumi
    Kameoka, Shingo
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Watanabe, Toshiaki
    Muro, Kei
    Baba, Hideo
    Yamamoto, Junji
    Mizunuma, Nobuyuki
    Tamagawa, Hiroshi
    Mochizuki, Izumi
    Kinugasa, Yusuke
    Kikuchi, Takashi
    Sugihara, Kenichi
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (03) : 908 - 915
  • [2] mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival
    Yasuno, Masamichi
    Uetake, Hiroyuki
    Ishiguro, Megumi
    Mizunuma, Nobuyuki
    Komori, Takamichi
    Miyata, Go
    Shiomi, Akio
    Kagimura, Tatsuo
    Sugihara, Kenichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 516 - 525
  • [3] mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival
    Masamichi Yasuno
    Hiroyuki Uetake
    Megumi Ishiguro
    Nobuyuki Mizunuma
    Takamichi Komori
    Go Miyata
    Akio Shiomi
    Tatsuo Kagimura
    Kenichi Sugihara
    International Journal of Clinical Oncology, 2019, 24 : 516 - 525
  • [4] A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC 0808)
    Uetake, Hiroyuki
    Yasuno, Masamichi
    Ishiguro, Megumi
    Kameoka, Shingo
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Watanabe, Toshiaki
    Muro, Kei
    Baba, Hideo
    Yamamoto, Junji
    Mizunuma, Nobuyuki
    Tamagawa, Hiroshi
    Mochizuki, Izumi
    Kinugasa, Yusuke
    Matsubara, Yoshihiro
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC0808): Final analysis for survival.
    Tamagawa, Hiroshi
    Uetake, Hiroyuki
    Ishiguro, Megumi
    Mizunuma, Nobuyuki
    Kinugasa, Yusuke
    Mochizuki, Izumi
    Hamaguchi, Tetsuya
    Hasegawa, Junichi
    Katsumata, Kenji
    Ishibashi, Keiichiro
    Ogata, Yutaka
    Takii, Yasumasa
    Ooshiro, Mitsuru
    Kagimura, Tatsuo
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection
    Wong, R.
    Saffery, C.
    Barbachano, Y.
    Chau, I.
    Valle, J.
    Hickish, T.
    Mudan, S.
    Khan, A.
    Chua, Y. J.
    Cunningham, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 344 - 345
  • [7] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
    Uetake, Hiroyuki
    Emi, Yasunori
    Yamanaka, Takeharu
    Muro, Kei
    Oki, Eiji
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
    Takahashi, Takao
    Ishida, Kazuyuki
    Emi, Yasunori
    Sakamoto, Michiie
    Imura, Johji
    Aishima, Shinichi
    Muro, Kei
    Uetake, Hiroyuki
    Oki, Eiji
    Katayose, Yu
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    CANCERS, 2022, 14 (18)
  • [9] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Eiji Oki
    Yasunori Emi
    Takeharu Yamanaka
    Hiroyuki Uetake
    Kei Muro
    Takao Takahashi
    Takeshi Nagasaka
    Etsuro Hatano
    Hitoshi Ojima
    Dai Manaka
    Tetsuya Kusumoto
    Yu Katayose
    Toshiyoshi Fujiwara
    Kazuhiro Yoshida
    Michiaki Unno
    Ichinosuke Hyodo
    Naohiro Tomita
    Kenichi Sugihara
    Yoshihiko Maehara
    British Journal of Cancer, 2019, 121 : 222 - 229
  • [10] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Oki, Eiji
    Emi, Yasunori
    Yamanaka, Takeharu
    Uetake, Hiroyuki
    Muro, Kei
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
12345